Access purpose-built immune monitoring and biomarker services to support your vaccine and therapy development across infectious diseases.
Precisely characterize cellular immunity with our comprehensive suite of immune monitoring and immunoassay biomarker services built for vaccine and therapy development.
Whether your program requires neutralizing antibodies measurement, cell-mediated immunity tracking, or multiplexed cytokine profiling, CellCarta partners with large pharma and biotech companies to develop and validate these assays . With deep expertise in cell-mediated immunity, our teams use a platform agnostic approach to monitor key clinical endpoints.
Don’t see your indication? Contact us about custom solutions.
Contact Us
Customized disease biomarker panels for Lyme disease research panels.
Quantitative biomarker measurement and immune monitoring to support HIV/AIDS clinical trials.
Cellular and humoral immune response monitoring for influenza vaccine programs.
Biomarker development and clinical testing for hepatitis B and hepatitis C programs.
Assay development for tuberculosis, dengue fever, malaria, brucellosis, and more.
Characterize immune responses across clinical phases of infectious disease trials with our suite of complex immune monitoring capabilities, including:
Advance your vaccine program with assays designed to characterize cellular and antibody-mediated immunity. Our teams can develop and validate assays built around your specific pathogen and trial timeline, including:
For studies interested in MHC peptide analysis and characterizing how the immune system identifies non-self antigens, CellCarta can support these investigations using high-resolution mass spectrometry, HLA typing, and advanced bioinformatic tools.
Our workflow directly detects presented peptides with a high degree of clarity, supporting immune monitoring and infectious disease research applications.
Generate validated, regulatory-ready biomarker data and perform quantitative measurements for clinical trials for a wide range of infectious diseases with our state-of-the-art mass spectrometry and flow cytometry platforms.
Characterize immune responses across clinical phases of infectious disease trials with our suite of complex immune monitoring capabilities, including:
Advance your vaccine program with assays designed to characterize cellular and antibody-mediated immunity. Our teams can develop and validate assays built around your specific pathogen and trial timeline, including:
For studies interested in MHC peptide analysis and characterizing how the immune system identifies non-self antigens, CellCarta can support these investigations using high-resolution mass spectrometry, HLA typing, and advanced bioinformatic tools.
Our workflow directly detects presented peptides with a high degree of clarity, supporting immune monitoring and infectious disease research applications.
Generate validated, regulatory-ready biomarker data and perform quantitative measurements for clinical trials for a wide range of infectious diseases with our state-of-the-art mass spectrometry and flow cytometry platforms.
Access a wide range of validated platforms for infectious disease research.
Identify, quantify, and monitor immune cell populations with high-parameter flow cytometry panels, with expert guidance on panel design, data analysis, and reporting. With access to a wide range of leading flow cytometry platforms, including the spectral CYTEK Aurora platform, our workflows can support all sample types.
Detect cytokines and measure antigen-specific T- and B-cell responses with ELISpot and FluoroSpot assays customized to your specific antigen. Commercial assays and custom development is available, with validation specific to your study’s specifications.
Profile cytokines, chemokines, and inflammation markers from small sample volumes with the MSD platform, delivering high-throughput, multiplexed data from as little as 25 µL of serum or plasma. MSD’s low limit of detection and broad dynamic ranges make it a suitable platform for targeted protein quantification in infectious disease programs.
Scientific Publication
Two randomized Phase II trials of a plant-derived quadrivalent influenza vaccine candidate enrolled 750 adults across two age groups to assess safety, humoral response, and cell-mediated immunity.
ICS assays by flow cytometry, delivered by CellCarta, showed the 30 µg dose produced the most consistent responses in both cohorts, directly informing the dose taken forward to Phase III.
Scientific Publication
The first-in-human Phase I trial of HB-101, a replication-deficient Lymphocytic Choriomeningitis Virus (LCMV) vector-based vaccine against cytomegalovirus, evaluated safety and immunogenicity in 54 participants.
Using ICS and ELISpot assays, developed by CellCarta, the trial characterized dose-dependent polyfunctional CD8 T-cell and neutralizing antibody responses, providing the data used to justify further clinical development.
Deep cell-mediated immunity expertise, accredited labs, and two decades of infectious disease research.
Cell-Mediated Immunity Expertise
Platform Agnostic Workflow
Global Lab Network
Validation for Any Endpoints
Close Collaboration with Sponsors
Blog
Blog
Publication
CellCarta supports a broad range of infectious disease indications, including COVID-19, HIV/AIDS, hepatitis B and C, influenza, tuberculosis, dengue fever, malaria, flu, and brucellosis. Our teams have developed and validated assays for both clinical trials and biomarker research programs across these areas. If your indication is not listed, you can contact us to discuss custom assay development options.
Our vaccine support capabilities include ICS assays by flow cytometry to measure intracellular cytokine expression at the single-cell level, ELISpot and FluoroSpot assays for T-cell and B-cell cytokine secretion measurement, and MSD for multiplexed cytokine profiling. All assays can be customized to specific antigens and validated for exploratory, secondary, or primary clinical trial endpoints in turnaround times aligned with your trial timeline.
Yes. CellCarta has a demonstrated track record of rapidly developing and validating custom assays for novel pathogens. During the COVID-19 pandemic, our teams partnered with biopharma companies to quickly develop SARS-CoV-2-specific ICS, ELISpot and FluoroSpot assays for use in clinical trials. Our teams can adapt established assay formats to new antigens and validate them to meet primary or secondary endpoint requirements.
